title: [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl TN antigen: (2). Evaluation of clinical significance. STN Study Group].
abstract: The clinical significance of serum sialyl Tn antigen as a tumor marker was evaluated using "STN Otsuka" kits. Results indicated that the antigen was frequently elevated in sera from patients with ovarian cancers (43.1%, 140/325), including serous cystadenocarcinoma (51.6%, 63/122), mucinous cystadenocarcinoma (55.6%, 30/54), endometrioid carcinoma (56.5%, 13/23), and mesonephroid carcinoma (40.0%, 6/15). The positive frequency of sialyl Tn antigen in patients with ovarian carcinoma was less than the frequency of CA 125 (75.5%, 194/257) or sialyl SSEA-1 (47.2% 83/176). However, the false positive rate of sialyl Tn antigen in patients with benign gynecological disorders (3.7%, 15/401) was much lower than the false positive rates of other antigens; such as CA 125 (48.4%, 155/320) and sialyl SSEA-1 (19.2%, 51/266). The serum level of sialyl Tn antigen reflected the clinical activity of the disease quite well in patients with ovarian cancers. The sialyl Tn antigen was concluded to be a useful serum tumor marker for ovarian cancers.
authors.forename: H
authors.initials: H
authors.lastname: Imura
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.forename: H
authors.initials: H
authors.lastname: Ohkura
authors.forename: M
authors.initials: M
authors.lastname: Ishii
authors.forename: H
authors.initials: H
authors.lastname: Ariyoshi
authors.forename: J
authors.initials: J
authors.lastname: Endo
authors.forename: M
authors.initials: M
authors.lastname: Kitao
authors.forename: I
authors.initials: I
authors.lastname: Takeda
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Inoue
mesh_terms: D000951:Antigens, Neoplasm / Q000032:analysis*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003536:Cystadenocarcinoma / Q000097:blood; D004715:Endometriosis / Q000097:blood; D005260:Female; D006017:Glycolipids / Q000032:analysis; D006801:Humans; D016256:Lewis X Antigen; D008649:Mesonephroma / Q000097:blood; D010051:Ovarian Neoplasms / Q000097:blood*; D011863:Radioimmunoassay; D011933:Reagent Kits, Diagnostic
chemical_list: D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D006017:Glycolipids; D016256:Lewis X Antigen; D011933:Reagent Kits, Diagnostic; C055491:sialosyl-Tn antigen